PEPG - NASDAQ
PepGen Inc.
$1.46
+3.0%PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotPepGen Inc. Management Team
Mr. Noel P. Donnelly M.B.A.
Chief Financial Officer
Compensation
$633,705
Ms. Emiko Bryant
Chief of Staff, HR & Operations
Dr. Paul D. Streck M.B.A., M.D.
Executive Vice President and Head of Research & Development
Compensation
$332,733
Dr. Michael Gait Ph.D.
Founder & Scientific Advisory Board Member
Ms. Mary Beth DeLena J.D.
General Counsel & Secretary
Dr. James G. McArthur Ph.D.
President, Chief Executive Officer, Treasurer, Secretary & Director
Compensation
$850,668
Dr. Hayley Parker Ph.D.
Senior Vice President of Global Regulatory Affairs
Dr. Afsaneh Mohebbi Ph.D.
Senior Vice President of Portfolio and Program Management
Mr. Kyle Breidenstine CPA, M.B.A.
Vice President of Finance & Controller
PepGen Inc. Insider Positioning
During the last 12 months, insiders have purchased $30.78M and sold $13K worth of PEPG shares, resulting in $30.77M of net buying activity.
3 Months
0
0.00
1.2K
1.74K
-2K
-$2K
3-6 Months
0
0.00
1.8K
11.41K
-11K
-$11K
6-9 Months
9.6M
30.64M
0
0.00
+30.6M
+$30.64M
9-12 Months
96.0K
144.96K
0
0.00
+145K
+$145K
Top Buyers
Ra Capital Management, L.P.
Director, 10 Percent Owner:
$30.02M
Oxford Science Enterprises Plc
Other: Former 10% Owner
$640K
Dable Habib J
Director
$24K
Resnick Joshua
Director
$24K
Mayer Howard
Director
$24K
Top Sellers
Streck Paul
Officer: Evp, Head Of R&D
$11K
Kasraian Kasra
Officer: Chief Technical Officer
$2K
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $30.77M net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Exceptional buy/sell ratio. Buying dramatically outweighs selling—one of the strongest possible insider signals.
Recent Trend (3 Months)
Heavy recent selling activity. Recent insider sales notably exceed purchases—may warrant investigation into company developments.
Insider Participation
5 insider buyers vs. 2 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
PEPG - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 18, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 25, 2025 | June 04, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 26, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 22, 2023 | 2023 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.